Scientists Are Using Microparticles To Develop a Self-Boosting Vaccine

Scientists Are Using Microparticles, to Develop a, Self-Boosting Vaccine.

'Newsweek' reports that scientists are developing a one-jab, self-boosting vaccine that can deliver multiple doses at different times.

According to new research, one shot could provide multiple rounds of inoculation thanks to microparticles.

Scientists claim the microparticles could be used to combat a number of illnesses, including measles and COVID.

The team at MIT's Koch Institute for Integrative Cancer Research in Cambridge, Massachusetts, says the technology could be particularly useful for administering childhood vaccinations.

This is a platform that can be broadly applicable to all types of vaccines, including recombinant protein-based vaccines, DNA-based vaccines, even RNA-based vaccines, Dr. Ana Jaklenec, senior author of the study, via 'Newsweek'.

Understanding the process of how the vaccines are released, which is what we described in this paper, has allowed us to work on formulations that address some of the instability that could be induced over time, Dr. Ana Jaklenec, senior author of the study, via 'Newsweek'.

'Newsweek' reports that the particles are made from PLGA, a biocompatible polymer already approved for use in medical and prosthetic devices.

.

We believe these core shell particles have the potential to create a safe, single-injection, self-boosting vaccine in which a cocktail of particles with different release times can be created by changing the composition, Professor Robert Langer, co-senior author of the study, via 'Newsweek'.

Such a single injection approach has the potential to not only improve patient compliance but also increase cellular and humoral immune responses to the vaccine, Professor Robert Langer, co-senior author of the study, via 'Newsweek'.

Such a single injection approach has the potential to not only improve patient compliance but also increase cellular and humoral immune responses to the vaccine, Professor Robert Langer, co-senior author of the study, via 'Newsweek'